Washington Post
Abbott Laboratories presented atrasentan, which has the trade name Xinlay, as a treatment for men with an advanced stage of prostate cancer that has spread to the bone. But the FDA's Oncologic Drugs Advisory Committee voted unanimously against recommending it.
More...
|